361 related articles for article (PubMed ID: 26637324)
1. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
2. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
Albertsen PC; Klotz L; Tombal B; Grady J; Olesen TK; Nilsson J
Eur Urol; 2014 Mar; 65(3):565-73. PubMed ID: 24210090
[TBL] [Abstract][Full Text] [Related]
4. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Greiman AK; Keane TE
Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
[TBL] [Abstract][Full Text] [Related]
5. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
Crawford ED; Hafron JM; Debruyne F; Wallis C; Chang S; Garnick MB
J Urol; 2024 Jan; 211(1):63-70. PubMed ID: 37796473
[TBL] [Abstract][Full Text] [Related]
7. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
9. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
10. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxicity of Androgen Deprivation Therapy.
Boland J; Choi W; Lee M; Lin J
Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
[TBL] [Abstract][Full Text] [Related]
12. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Miller K
Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
[TBL] [Abstract][Full Text] [Related]
14. Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.
Dragomir A; Touma N; Hu J; Perreault S; Aprikian AG
J Natl Compr Canc Netw; 2023 Feb; 21(2):163-171. PubMed ID: 36791755
[TBL] [Abstract][Full Text] [Related]
15. [Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update].
von Amsberg G; Thiele H; Merseburger A
Urologe A; 2021 Nov; 60(11):1450-1457. PubMed ID: 34213627
[TBL] [Abstract][Full Text] [Related]
16. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
17. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk with androgen deprivation therapy.
Rosenberg MT
Int J Clin Pract; 2020 Mar; 74(3):e13449. PubMed ID: 31755635
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Freedland SJ; Abrahamsson PA
Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.
Davey P; Kirby MG
World J Urol; 2021 Feb; 39(2):307-315. PubMed ID: 32979057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]